IGS1 Stock Chart & Stats
€0.26
€0.00(0.00%)
At close: 4:00 PM EDT
€0.26
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.21 - €0.36
Previous CloseN/A
Volume0.00
Average Volume (3M)540.00
Market Cap
€22.63M
Enterprise Value€26.51M
Total Cash (Recent Filing)€354.00K
Total Debt (Recent Filing)€1.08M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 18, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding103,384,010
10 Day Avg. Volume403
30 Day Avg. Volume540
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.35Price Target Upside1957.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€947.21K
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow debt relative to equity reduces near-term balance-sheet strain and gives IGC more flexibility than a highly levered biotech. This structure can help preserve funding options while the company advances clinical programs, although continued losses could still erode that advantage over time.
Financing AccessDebt conversion directly reduces liabilities while increasing equity, and the amended loan facility preserves access to credit for development activities. Together, these actions provide financial runway and support near-term execution, even though they also show that external funding remains important.
Positive Gross MarginA positive gross margin indicates that reported revenue contributes toward costs before operating expenses, providing a potential foundation for improvement if product or licensing revenue expands. The reduced severity of losses versus earlier periods is also a constructive, though still limited, operating trend.
Bears Say
Declining Revenue BaseA very small and declining revenue base limits IGC’s ability to fund research and development internally or demonstrate commercial traction. Without sustained revenue growth, the company remains dependent on financing, licensing, or other non-recurring sources while its clinical pipeline advances.
Severe UnprofitabilityLosses remain far out of proportion to current revenue, showing that the existing cost structure is not yet supported by operations. Persistent deep unprofitability can consume shareholder capital, constrain strategic choices, and leave financial performance highly dependent on successful clinical and regulatory progress.
Negative Cash GenerationSustained negative operating and free cash flow means IGC cannot currently finance its activities from internally generated funds. The sharp TTM deterioration in free cash flow increases reliance on equity, debt, or strategic transactions and could pressure the company if funding access weakens.
IGC Pharma News
IGS1 FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was €0.21 and its highest was €0.36 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is €22.63M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Nov 18, 2026 which is in 31 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 15, 2026. The company reported -€0.018 earnings per share for the quarter.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 103,384,010 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -€0.018 in its last earnings report. Following the earnings report the stock price went up 2.479%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in DE:IGS1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGS1 Stock 12 Month Forecast
Average Price Target
€5.35
▲(1957.72% Upside)